Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
-
Shares outstanding
-
41.1M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
+16.8M
-
Total reported value, excl. options
-
$278M
-
Value change
-
+$278M
-
Number of buys
-
29
-
Price
-
$16.55
Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q1 2021
29 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q1 2021.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 41.1M outstanding shares and own 40.87% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (2.59M shares), Artal Group S.A. (2.26M shares), Redmile Group, LLC (2.09M shares), ORBIMED ADVISORS LLC (1.58M shares), BOXER CAPITAL, LLC (1.54M shares), RA CAPITAL MANAGEMENT, L.P. (1.39M shares), Farallon Capital Management, L.L.C. (1M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (800K shares), PERCEPTIVE ADVISORS LLC (755K shares), and JPMORGAN CHASE & CO (626K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.